The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating interleukin-6, but not of tumour necrosis factor-alpha

Clinical and Experimental Rheumatology

Volumn 29, Issue 1 SUPPL. 64, 2011, Pages

  Antonelli, Alessandro ^a   Ferri, C ^b   Ferrari, S M ^a   Di Domenicantonio, A ^a   Ferrari, P ^a   Pupilli, C ^c   Nicolini, A ^a   Zignego, A L ^c   Marchi, S ^a   Fallahi, P ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Autoimmune thyroid disorders; Cryoglobulinemia; HCV; IL 6; TNF

Indexed keywords

INTERLEUKIN 6; THYROTROPIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE THYROIDITIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; DISEASE DURATION; ECHOGRAPHY; FEMALE; HUMAN; MALE; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PURPURA; THYROTROPIN BLOOD LEVEL; WEAKNESS; HEPATITIS C; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-6; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; THYROIDITIS, AUTOIMMUNE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 79960426065     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. FERRI C, LA CIVITA L, LONGOMBARDO G, GRECO F, BOMBARDIERI S: Hepatitis C virus and mixed cryoglobulinaemia. Eur J Clin Invest 1993; 23: 399-405.
2. ANTONELLI A, FERRI C, FERRARI SM, COLACI M, FALLAHI P: Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008; 8: 18-23.
3. ANTONELLI A, FERRI C, FERRARI SM, COLACI M, SANSONNO D, FALLAHI P: Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 2009; 5: 26-34.
4. ANTONELLI A, FERRI C, GALEAZZI M et al.: HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 2008; 26 (Suppl. 48): S39-47.
5. ANTONELLI A, FERRI C, FALLAHI P et al.: High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 2008; 103: 2488-94.
6. KISHIMOTO T, AKIRA S, TAGA T: Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992; 258: 593-7.
7. HIRANO T: Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992; 62 (1 Pt 2): S60-5.
8. HIRANO T, YASUKAWA K, HARADA H et al: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73-6.
9. BAUMANN H, JAHREIS GP, SAUDER DN, KOJ A: Human keratinocytes and monocytes release factors which regulate the synthesis of major acute phase plasma proteins in hepatic cells from man, rat, and mouse. J Biol Chem 1984; 259: 7331-42.
10. UYTTENHOVE C, COULIE PG, VAN SNICK J: T cell growth and differentiation induced by interleukin-HPI/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med 1988; 167: 1417-27.
11. LEARY AG, IKEBUCHI K, HIRAI Y et al.: Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha. Blood 1988; 71: 1759-63.
12. HYAMS JS, FITZGERALD JE, TREEM WR, WYZGA N, KREUTZER DL: Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993; 104: 1285-92.
13. FELDMANN G, NISCHALKE HD, NATTERMANN J et ai: Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 4491-8.
14. FALASCA K, MANCINO P, UCCIFERRI C et al.: Inflammatory cytokines and S-100b protein in patients with hepatitis C infection and cryoglobulinemias. Clin Invest Med 2007; 30: E167-76.
15. ANTONELLI A, FERRI C, FERRARI SM et al: High circulating levels of N-terminal probrain natriuretic peptide and interleukin 6 in patients with mixed cryoglobulinemia. J Med Virol 2010; 82: 297-303.
16. ANTONELLI A, FERRI C, FERRARI SM et al: Serum levels of proinflammatory cytokines interleukin-1 beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. Arthritis Rheum 2009; 60: 3841-7.
17. ANTONELLI A, FERRI C, FERRARI SM et al.: High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia. Clin Rheumatol 2009; 28: 1179-85.
18. ANTONELLI A, FERRI C, FALLAHI P et al: High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 2008; 42: 137-43.
19. BARTALENA L, BROGIONI S, GRASSO L, MARTINO E: Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration. J Endocrinol Invest 1993; 16: 213-8.
20. BARTALENA L, GRASSO L, BROGIONI S, AGHINI-LOMBARDI F, BRAVERMAN LE, MARTINO E: Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994; 78: 423-7.
21. MOLNAR I, BALAZS C: High circulating IL-6 level in Graves' ophthalmopathy. Autoimmunity 1997; 25: 91-6.
22. PAPANAS N, PAPAZOGLOU D, PAPATHEODOROU K, ANTONOGLOU C, KOTSIOU S, MALTEZOS E: Thyroxine replacement dose in patients with Hashimoto disease: a potential role for interleukin-6. Cytokine 2006; 35: 166-70.
23. FIGUEROA-VEGA N, ALFONSO-PÉREZ M, BENEDICTO I, SÁNCHEZ-MADRID F, GONZÁLEZ-AMARO R, MARAZUELA M: Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis. J Clin Endocrinol Metab 2010; 95: 953-62.
24. ANTONELLI A, FERRI C, FALLAHI P et al.: Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology 2004; 43: 238-40.
25. ANTONELLI A, FERRI C, FALLAHI P et al.: Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM 2004; 97: 499-506.
26. ANTONELLI A, ROTONDI M, FALLAHI P et al.: Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 2005; 152: 171-7.
27. ANTONELLI A, FERRI C, FALLAHI P: Thyroid cancer in patients with hepatitis C infection. JAMA 1999; 281: 1588.
28. HIRANO T, MATSUDA T, TURNER M et al.: Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988; 18: 1797-801.
29. GRISIUS MM, BERMUDEZ DK, FOX PC: Salivary and serum interleukin 6 in primary Sjögren's syndrome. J Rheumatol 1997; 24: 1089-91.
30. STUART RA, LITTLEWOOD AJ, MADDISON PJ, HALL ND: Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995; 13: 17-22.
31. KAMIMURA D, ISHIHARA K, HIRANO T: IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003; 149: 1-38.
32. HEUER M, AUST G, ODE-HAKIM S, SCHERBAUM WA: Different cytokine mRNA profiles in Graves' disease, Hashimoto's thyroiditis, and nonautoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid 1996; 6: 97-106.
33. AHMAD L, PARKES A, LAZARUS J et al.: Interleukin-6 levels are not increased in women with postpartum thyroid dysfunction. Thyroid 1998; 8: 371-5.
34. FRANCIOTTA D, MARTINO G, ZARDINI E et al.: Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192-8.
35. GANGUR V, SIMONS FE, HAYGLASS KT: Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. Faseb J 1998; 12: 705-13.
36. MAHAD DJ, HOWELL SJ, WOODROOFE MN: Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 498-502.
37. ANTONELLI A, FALLAHI P, ROTONDI M et al.: Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006; 154: 651-8.
38. ANTONELLI A, ROTONDI M, FALLAHI P et al.: Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxford) 2006; 64: 189-95.
39. LECUBE A, HERNÁNDEZ C, GENESCÀ J, SIMÓ R: Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care 2006; 29: 1096-101.
40. RIORDAN SM, SKINNER NA, KURTOVIC J et al.: Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury. Inflamm Res 2006; 55: 279-85.
41. NEUMAN MG, BENHAMOU JP, MARCELLIN P et al.: Cytokine-chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 2007; 149: 126-36.
42. LOFFREDA S, MURATORI P, MURATORI L, MELE L, BIANCHI FB, LENZI M: Enhanced monocyte Th1 cytokine production in HCV-infected cryoglobulinemic patients. J Hepatol 2003; 38: 230-6.
43. SAADOUN D, BOYER O, TREBEDEN-NEGRE H et al.: Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. J Hepatol 2004; 41: 1031-7.
44. PHENEKOS C, VRYONIDOU A, GRITZAPIS AD, BAXEVANIS CN, GOULA M, PAPAMICHAIL M: Th1 and Th2 serum cytokine profiles characterise patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2). Neuroimmunomodulation 2004; 11: 209-13.